Deciphera Pharmaceuticals LLC (DCPH)
$25.61
$0.04
(0.16%)
As on 10-Jun-2024 16:09EDT
Market cap
$2,213 Mln
Revenue (TTM)
$175 Mln
P/E Ratio
--
P/B Ratio
7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-49 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-4.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.2
-
Face value
--
-
Shares outstanding
86,476,000
9 Years Aggregate
CFO
$-1,089.21 Mln
EBITDA
$-1,337.26 Mln
Net Profit
$-1,324.59 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Deciphera Pharmaceuticals LLC (DCPH)
| 58.8 | 0.9 | 51.2 | 82.7 | -8.9 | 3.2 | -- |
|
BSE Sensex*
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|
|
Deciphera Pharmaceuticals LLC (DCPH)
| -1.6 | 67.8 | -82.9 | -8.3 | 196.5 | -7.4 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Deciphera Pharmaceuticals LLC (DCPH)
|
25.6 | 2,212.9 | 174.9 | -190.4 | -118.4 | -54.6 | -- | 7.0 |
| 0.1 | 3.6 | 0.3 | -95.1 | -21,828.5 | -265.1 | -- | 0.3 | |
| 2.1 | 6.0 | 0.1 | -6.2 | -15,087.2 | -15.2 | -- | 1.9 | |
| 22.9 | 71.7 | 0.0 | -24.8 | -- | -81.5 | -- | 2.1 |
Shareholding Pattern
View DetailsAbout Deciphera Pharmaceuticals LLC (DCPH)
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the... United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd. Read more
-
President, CEO & Director
Mr. Steven L. Hoerter
-
President, CEO & Director
Mr. Steven L. Hoerter
-
Headquarters
Waltham, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Deciphera Pharmaceuticals LLC (DCPH)
What is the current share price of Deciphera Pharmaceuticals LLC (DCPH) Today?
The share price of Deciphera Pharmaceuticals LLC (DCPH) is $25.61 (NASDAQ) as of 10-Jun-2024 16:09 EDT. Deciphera Pharmaceuticals LLC (DCPH) has given a return of -8.9% in the last 3 years.
What is the current PB & PE ratio of Deciphera Pharmaceuticals LLC (DCPH)?
Since, TTM earnings of Deciphera Pharmaceuticals LLC (DCPH) is negative, P/E ratio is not available.
The P/B ratio of Deciphera Pharmaceuticals LLC (DCPH) is 7.00 times as on 10-Jun-2024, a 72 premium to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-7.03
|
3.91
|
|
2022
|
-6.96
|
3.65
|
|
2021
|
-1.91
|
1.86
|
|
2020
|
-11.99
|
5.88
|
|
2019
|
-13.98
|
4.90
|
What is the 52 Week High and Low of Deciphera Pharmaceuticals LLC (DCPH)?
The 52-week high and low of Deciphera Pharmaceuticals LLC (DCPH) are Rs -- and Rs -- as of 14-Jun-2026.
What is the market cap of Deciphera Pharmaceuticals LLC (DCPH)?
Deciphera Pharmaceuticals LLC (DCPH) has a market capitalisation of $ 2,213 Mln as on 10-Jun-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Deciphera Pharmaceuticals LLC (DCPH)?
Before investing in Deciphera Pharmaceuticals LLC (DCPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.